| Literature DB >> 34675273 |
Miguel F Tenreiro1,2, Henrique V Almeida1,2, Tomás Calmeiro3, Elvira Fortunato3, Lino Ferreira4,5, Paula M Alves1,2, Margarida Serra6,7.
Abstract
The extracellular matrix (ECM) of engineered human cardiac tissues corresponds to simplistic biomaterials that allow tissue assembly, or animal derived off-the-shelf non-cardiac specific matrices. Decellularized ECM from human cardiac tissue could provide a means to improve the mimicry of engineered human cardiac tissues. Decellularization of cardiac tissue samples using immersion-based methods can produce acceptable cardiac ECM scaffolds; however, these protocols are mostly described for animal tissue preparations. We have tested four methods to decellularize human cardiac tissue and evaluated their efficiency in terms of cell removal and preservation of key ECM components, such as collagens and sulfated glycosaminoglycans. Extended exposure to decellularization agents, namely sodium dodecyl sulfate and Triton-X-100, was needed to significantly remove DNA content by approximately 93% in all human donors. However, the biochemical composition of decellularized tissue is affected, and the preservation of ECM architecture is donor dependent. Our results indicate that standardization of decellularization protocols for human tissue is likely unfeasible, and a compromise between cell removal and ECM preservation must be established in accordance with the scaffold's intended application. Notwithstanding, decellularized human cardiac ECM supported human induced pluripotent-derived cardiomyocyte (hiPSC-CM) attachment and retention for up to 2 weeks of culture, and promoted cell alignment and contraction, providing evidence it could be a valuable tool for cardiac tissue engineering.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34675273 PMCID: PMC8531368 DOI: 10.1038/s41598-021-00226-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Cardiac tissue donor data. LV left ventricle, hiPSC-CM human induced pluripotent cardiomyocytes.
| Characteristics | Donor 1 | Donor 2 | Donor 3 | Donor 4 |
|---|---|---|---|---|
| Age | 69 | 67 | 67 | 61 |
| Sex | Male | Female | Female | Male |
| Cause of death | Intracerebral hemorrhage | Not disclosed | Not disclosed | Not disclosed |
| Reason for exclusion from transplantation | Not disclosed | Not disclosed | Not disclosed | Not disclosed |
| Tissue source | Myocardium, LV; No pathology associated | Myocardium Apex, LV; No pathology associated | Myocardium, LV; No pathology associated | Myocardium, LV; No pathology associated |
| Experimental allocation | Evaluation of decellularization protocols | Evaluation of decellularization protocols | Evaluation of decellularization protocols | Decellularization Method D; Recellularization with hiPSC-CM |
Figure 1Histological assessment of the different chemical-based decellularization methods attempted for human cardiac tissue. (a) Chemical-based decellularization methods tested for human cardiac tissue. The details regarding the solutions used and exposure duration applied are highlighted for each decellularization step. For each donor is shown: (b), (e), (h) Gross tissue morphology. Scale bars: 1 mm; (c), (f), (i) Hematoxylin & Eosin staining. Scale bars: 100 µm; (d), (g), (j) Masson’s Trichome staining. Scale bars: 100 µm.
Figure 2Biological characterization of chemical-based decellularized human cardiac tissue. (a) Double stranded DNA (dsDNA) content of native and decellularized cardiac tissue for all methods, normalized to tissue wet weight (n = 3; one-way ANOVA, F4,10 = 4.38, *p < 0.05 with Tukey’s multiple comparison test). (b) Immunofluorescence of nuclei (DAPI, white) in native and decellularized tissue through method D for each donor. Scale bars: 50 µm. (c) Number of DAPI + nuclei per cross-section area (n = 3; two-tailed unpaired t-test, ***p < 0.001). (d) Biochemical analysis for soluble collagen (n = 3; Kruskal–Wallis test, *p = 0.0229, *p < 0.05 with Dunnett’s multiple-comparison test), insoluble collagen (n = 3; one-way ANOVA, F4,10 = 2.304, following Tukey’s multiple comparison test), sulfated glycosaminoglycans (s-GAGs; n = 3; one-way ANOVA, F4,10 = 7.709, *p < 0.05 and **p < 0.01 with Tukey’s multiple comparison test) on native and decellularized cardiac tissue for all methods, normalized to tissue wet weight. The average of the 3 cardiac tissue donors was used as a representative value for the component in the myocardium. (e), (g), (i) Picro Sirius Red (PSR) and (f), (h), (j) Alcian Blue staining on native and decellularized tissue for all methods. Scale bars: 100 µm. Data are represented as mean ± SD.
Figure 3Scanning electron microscopy analysis of native and decellularized human cardiac tissue. (a) Architecture of native cardiac tissue and the decellularized scaffold using method D. Scale bars: 50 µm. (b) Density histogram of extracellular matrix fiber orientation of native and decellularized tissue using method D (n = 35–55 ROI analyzed per condition per tissue donor). (c) Anisotropy index (0—random alignment/isotropic array, 1—perfect alignment/purely anisotropic array) of native and decellularized tissue using method D (n = 3; two-tailed unpaired t-test). Data are represented as mean ± SD.
Figure 4Assessment of tissue formation capacity of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) on decellularized human cardiac tissue. (a) Hematoxylin & Eosin and (b) Masson’s Trichome staining of decellularized (method D) and recellularized tissue after 14 days of culture, at low (scale bars: 100 µm) and high magnification (scale bars: 50 µm). (c) Immunofluorescence micrograph of cardiac troponin T (cTNT, red) expression in decellularized tissue and recellularized tissue after 14 days of culture, and counterstained with DAPI (blue). Scale bar: 50 µm. (d) Density histogram of mean angular orientation of ventricular cardiomyocytes in native cardiac tissue and hiPSC-CM in recellularized tissue (n > 300 ROI analyzed per condition).